PARAGON-HF: Lessons Learned and Perspectives
José Francisco Kerr Saraiva
Isadora de Oliveira
An estimated 6.5 million Americans aged 20 and over have heart failure (HF) and projections show that the prevalence of HF will increase by 46% from 2012 to 2030,
resulting in over 8 million people with HF.1
Patients with HF can be stratified into diferente categories of left ventricular ejection fraction (LVEF), presenting different phenotypes in terms of demographics, clinical presentation, etiology and outcomes. The current classification comprises HF with reduced ejection fraction (EF) [EF ≤ 40% (HFrEF)], with intermediate EF [EF 40-50% (HFiEF), and preserved EF [EF ≥ 50% (HFpEF).2,3
Keywords: Heart Failure/physiopathology; Neprilysin/therapeutic use; Echocardiography/methods; Dysfunction Left Ventricular/abnormalities; Indicators of Morbidity and Mortality; Risk Factors; Valsartan/therapeutic use.